RG7834 (Synonyms: RO 7020322; (S)-RO0321)

Name: RG7834
Brand: MedChemExpress
SKU: HY-117650A
Rating: 5.0 (9 reviews)

Cat. No.: HY-117650A Purity: 99.29%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

RG7834 (RO 7020322) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC₅₀s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells.

For research use only. We do not sell to patients.

CAS No. : 2072057-17-9

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 9 publication(s) in Google Scholar

Other Forms of RG7834:

(R)-RG7834 Get quote

9 Publications Citing Use of MCE RG7834

Cell Imaging/Staining

Bio/Physico-chemical Assay

RT-PCR

: RG7834 purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Oct 10:e0092225. [Abstract]; Activation of HBV-RADARS corresponds to its target HBV RNA levels in HepG2.2.15. The results showed that treating cells with the HBV RNA destabilizing compound RG7834 (1 μM) (except for HBx mRNA) significantly reduced total HBV RNA and antigen expression, corresponding with a decrease in HBV RNA-mediated Gluc activation from the HBV-RADARS reporter.

: RG7834 purchased from MedChemExpress. Usage Cited in: Proc Natl Acad Sci U S A. 2024 Jun 4;121(23):e2316734121. [Abstract]; TENT4 inhibitor, RG7834 (1 μM; 1 h), impairs liquid-to-solid phase transition of Amyloid bodies. Numbers denote percentage of cells with intranucleolar foci.

: RG7834 purchased from MedChemExpress. Usage Cited in: Research Square Preprint. 2022 May.; Telomere lengths determined by Southern blot TRF analysis of gDNA prepared from WT_iPSC_F and R449G_iPSC_1 treated with RG7834 (1 μM), Cordycepin, or DMSO. The results showed that RG7834 partially restored telomere length in R449G_iPSC_1 (lanes 7).

: RG7834 purchased from MedChemExpress. Usage Cited in: Research Square Preprint. 2022 May.; Total RNA prepared from WT_iPSC_F and R449G_iPSC_1 cells treated with RG7834 (1 μM), Cordycepin, or DMSO was subjected to qRT–PCR for oligoadenylated hTR. Bar graph of the mean fold change relative to DMSO-treated samples and normalized to GAPDH, ATP5b, and HPRT. The results showed that RG7834 (1 μM) led to a decrease in the proportion of oligoadenylated hTR.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

IC50: 2.8 nM (HBsAg), 2.6 nM (HBeAg), 3.2 nM (HBV DNA)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
HepG2 2.2.15	CC₅₀	> 10 μM Compound: 1; RG-7834	Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability measured after 4 days by CellTiter-Glo reagent based assay Cytotoxicity against human HepG2.2.15 cells assessed as reduction in cell viability measured after 4 days by CellTiter-Glo reagent based assay	[PMID: 34267883]
HepG2 2.2.15	CC₅₀	> 50 μM Compound: (S)-64; RG7834	Cytotoxicity against human HepG2.2.15 cells by CCK-8 assay Cytotoxicity against human HepG2.2.15 cells by CCK-8 assay	[PMID: 30286292]
HepG2 2.2.15	EC₅₀	1.2 nM Compound: RG7834	Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBsAg level incubated for 6 days by microplate-based chemiluminescence immunoassay Antiviral activity against HBV infected in human HepG2.2.15 cells assessed as inhibition of HBsAg level incubated for 6 days by microplate-based chemiluminescence immunoassay	[PMID: 38190324]
HepG2 2.2.15	IC₅₀	0.001 μM Compound: 1; RG7834	Inhibition HBsAg secretion in human HepG2.2.15 cells treated for 3 days followed by medium replacement without compound measured after 2 days by CLIA Inhibition HBsAg secretion in human HepG2.2.15 cells treated for 3 days followed by medium replacement without compound measured after 2 days by CLIA	[PMID: 38428537]

In Vitro

RG7834 ((S)-(+)-64) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC₅₀s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells^[1].
RG7834 has no activity against CYP3A4, CYP2D6, CYP2C9 (IC₅₀s >50 μM) or hERG channel^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

RG7834 (4 mg/kg, twice daily for 21 days) shows anti-HBV efficacy in HBV-infected human liver chimeric uPA-SCID mice^[1].
RG7834 (2, 14.5 mg/kg, p.o.) exhibits good oral bioavail ability, with a half-life of 4.9 h in mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	HBV-infected human liver chimeric uPA-SCID mice^[1]
Dosage:	4 mg/kg
Administration:	Twice daily for 21 days
Result:	Reduced both HBsAg and HBeAg, also decreased serum HBV DNA by 0.6 log10 in mice.

Clinical Trial

Molecular Weight

401.45

Formula

C₂₂H₂₇NO₆

CAS No.

2072057-17-9

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(O)C1=CN2[C@@H](CC3=CC(OCCCOC)=C(C=C3C2=CC1=O)OC)C(C)C

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (311.37 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.4910 mL	12.4549 mL	24.9097 mL
5 mM	0.4982 mL	2.4910 mL	4.9819 mL
10 mM	0.2491 mL	1.2455 mL	2.4910 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.87 mg/mL (7.15 mM); Clear solution
Protocol 2

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (5.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 3

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (5.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 4

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (5.18 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.29%

Select Batch:

Data Sheet (274 KB) SDS (252 KB)

COA (248 KB) HNMR (115 KB) RP-HPLC (224 KB) MS (68 KB)

Handling Instructions (2659 KB)

References

[1]. Han X, et al. Discovery of RG7834: The First-in-Class Selective and Orally Available Small Molecule Hepatitis B Virus Expression Inhibitor with Novel Mechanism of Action. J Med Chem. 2018 Oct 4. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.4910 mL	12.4549 mL	24.9097 mL	62.2743 mL
	5 mM	0.4982 mL	2.4910 mL	4.9819 mL	12.4549 mL
	10 mM	0.2491 mL	1.2455 mL	2.4910 mL	6.2274 mL
	15 mM	0.1661 mL	0.8303 mL	1.6606 mL	4.1516 mL
	20 mM	0.1245 mL	0.6227 mL	1.2455 mL	3.1137 mL
	25 mM	0.0996 mL	0.4982 mL	0.9964 mL	2.4910 mL
	30 mM	0.0830 mL	0.4152 mL	0.8303 mL	2.0758 mL
	40 mM	0.0623 mL	0.3114 mL	0.6227 mL	1.5569 mL
	50 mM	0.0498 mL	0.2491 mL	0.4982 mL	1.2455 mL
	60 mM	0.0415 mL	0.2076 mL	0.4152 mL	1.0379 mL
	80 mM	0.0311 mL	0.1557 mL	0.3114 mL	0.7784 mL
	100 mM	0.0249 mL	0.1245 mL	0.2491 mL	0.6227 mL

RG7834 Related Classifications

Infection

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

RG78342072057-17-9RO 7020322(S)-RO0321RG 7834RG-7834RO7020322RO-7020322HBVHepatitis B virusInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

RG7834 (Synonyms: RO 7020322; (S)-RO0321)

Customer Review

Other Forms of RG7834:

RG7834 Related Antibodies

9 Publications Citing Use of MCE RG7834

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

RG7834 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

RG7834 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report